trending Market Intelligence /marketintelligence/en/news-insights/trending/wl7x-jnAHMKaTElEn7RlGA2 content esgSubNav
In This List

Mylan receives tentative US approval for generic HIV treatment

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Mylan receives tentative US approval for generic HIV treatment

The U.S Food and Drug Administration granted tentative approval to Mylan NV's generic HIV treatment under the U.S. President's Emergency Plan for AIDS Relief.

The anti-retroviral treatment, known as TDF-3TC-DTG, or TLD, is recommended as the first line of treatment for patients in developing countries. The drug combines the active ingredients from three brand-name medicines: ViiV Healthcare's Tivicay and Epivir, and Gilead Sciences Inc.'s Viread.

The U.S. President's Emergency Plan for AIDS Relief is a U.S. government initiative to address the global HIV/AIDS epidemic, primarily in Africa.

ViiV Healthcare is majority owned by GlaxoSmithKline plc